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Problem statement
Very high-priced pharmaceuticals also known as “speci-
alty” drugs constitute a large and growing share of total
spending on health care in OECD countries. Due to the
lack of therapeutic alternatives and high perceived thera-
peutic value of the drugs, policies used to manage pharma-
ceutical spending are often impractical or ineffective in the
case of specialty drugs. In this environment, there is a
need to reformulate existing policies or develop new ones
that are best suited to managing this growing group of
products in a way that is consistent with the values and
objectives underlying the policy frameworks of publicly
financed health systems.
Objective
This study was undertaken to identify public policies
being used internationally in the management of high-
priced medicines and to evaluate their strengths and
weaknesses in terms of managing costs while promoting
affordable access to effective medicines.
Methods
The authors undertook reviews of the academic research
and grey literature to identify policies used in OECD
countries in the management of high-cost or specialty
drugs, and information on the impact of the policies
used on key outcomes. The review was supplemented
by information from original interviews with pharma-
ceutical policy experts in selected countries. The authors
compiled a list of policies being used and evidence on
their impact, then undertook a policy analysis aimed at
classifying the policies according to common features
and implementation effects.
Results
Preliminary results from this ongoing study indicate that
countries are employing a range of policy approaches in
the management of high-priced pharmaceuticals, including
price controls, delayed reimbursement decisions, applica-
tion of utilization controls and implementation of cost
sharing. However, in cases of nearly inelastic patient - as
when a drug’s therapeutic outcomes are perceived as very
valuable with no significant market competition - specialty
drug manufacturers succeed in obtaining effective sales
prices at unprecedented levels. Alternative policy formula-
tions, including those that shape the terms of the market
in which buyers and sellers interact, may be necessary if
policy-makers seek to change this paradigm.
Conclusions
Optimizing goals for management of high-cost pharma-
ceuticals may require trade-offs across them as informed
by value judgments, meaning that there is likely no single
best solution. Nevertheless, information on the strengths
and weaknesses of alternative policies can be useful in
efforts to choose appropriate policies in the face of
uncertainty.
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